A Phase 2 Trial Of PF-04856884 (CVX-060), A Selective Angiopoietin-2 (Ang-2) Binding CovX-body, In Patients With Recurrent Glioblastoma

Trial Profile

A Phase 2 Trial Of PF-04856884 (CVX-060), A Selective Angiopoietin-2 (Ang-2) Binding CovX-body, In Patients With Recurrent Glioblastoma

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2015

At a glance

  • Drugs PF 4856884 (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 22 Dec 2010 Trial location (USA) identified as reported by ClinicalTrials.gov.
    • 22 Dec 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 27 Oct 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top